Novo Nordisk A/S (CPSE: NOVO B)
Health Care · Pharmaceuticals · DK
Dkr265.15
-2.32% today · -11.0% 1Y
Public summary
A free snapshot of Novo Nordisk A/S, with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app Novo Nordisk A/S (CPSE: NOVO B) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $175.56B.
Over the last twelve months the share price has lost 11.0%, trading between 224.25 and 409.95.
Tweenvest scores Novo Nordisk A/S across four factors: quality 84/100, value 79/100, growth 63/100, dividend 96/100. Its strongest factor is dividend.
NOVO B price history
Key figures
- Market cap
- $175.56B
- Revenue (TTM)
- $50.70B
- P/E
- 10.65
- EPS
- 25.47
- Dividend yield
- 4.35%
- Beta (5Y)
- 0.37
- 52-week high
- Dkr409.95
- 52-week low
- Dkr224.25
- Avg volume (3M)
- —
- Shares outstanding
- 4.41B
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Roche Holding AGSWX: ROP | $381.70B | CHF399.20 | -1.04% |
| Merck & Co., Inc.NYSE: MRK | $339.66B | $132.12 | -4.11% |
| Novartis AGSWX: NOVN | $294.48B | CHF127.24 | -3.22% |
| AstraZeneca PLCLSE: AZN | $278.14B | £133.04 | -2.51% |
| Pfizer Inc.NYSE: PFE | $159.94B | $27.50 | -2.01% |
| Bristol-Myers Squibb CompanyNYSE: BMY | $121.75B | $58.12 | -2.42% |
| SanofiENXTPA: SAN | $113.30B | €83.79 | -2.85% |
| GSK plcLSE: GSK | $97.88B | £18.27 | -1.67% |